Polyrizon Says It Completed Contracting With All Five U.S. Clinical Sites For First-In-Human Study Of NASARIX Allergy Blocker, Planned To Enroll Up To 120 Patients

Loading news article.

Polyrizon Says It Completed Contracting With All Five U.S. Clinical Sites For First-In-Human Study Of NASARIX Allergy Blocker, Planned To Enroll Up To 120 Patients | WAPE

Polyrizon Says It Completed Contracting With All Five U.S. Clinical Sites For First-In-Human Study Of NASARIX Allergy Blocker, Planned To Enroll Up To 120 Patients

Article summary

Related companies

Comments —